Under which ministry does the Department of Pharmaceuticals, which runs the PRIP scheme, function?

The correct answer is about Rs 1,600 crore. That is the assistance the Department of Pharmaceuticals committed to the 41 projects cleared in the first call of the scheme. The figure matters because of what sits beside it: the projects are expected to draw a further Rs 3,020 crore of private money, so the whole research and development spend on them comes to roughly Rs 4,620 crore. Option A halves the government share and would not support a portfolio of this size. Option C and option D are both larger than the assistance actually sanctioned, and option D comes close to the private investment figure, which is exactly the confusion an examiner sets up when three related amounts appear in one release. The safe way to hold the fact is as a chain: assistance, then private investment, then the total.

The correct answer is New Medicines, which took 27 of the 41 approved projects. Option B, Complex Generics and Biosimilars, accounted for five projects, so it is the smallest of the three real categories rather than the largest. Option C, Novel Medical Devices, accounted for nine projects, which places it second but still well behind New Medicines. Option D, clinical trial infrastructure, is not one of the priority areas named in the announcement at all, and it is included to test whether a candidate recognises the three-way split the department actually uses. The same announcement gives two other splits worth remembering: 12 projects are at an early stage against 29 at a later stage, and 19 belong to startups and MSMEs against 22 to large companies.

The correct answer is TRL 1, 2 or 3. Start-ups and MSMEs taking up New Chemical Entity or New Biological Entity projects at those three readiness levels may apply under this exclusive track, and the department will support them to progress to higher levels but not beyond TRL 6. Option B describes the eligibility band of the Later Stage track, which is open to industry as well as start-ups and MSMEs, so it is the closest and most tempting wrong choice. Option C names levels that fall outside what any of the tracks admit for entry. Option D is wrong because the scheme sets definite bands for each track rather than admitting every level. Note that the Early Stage track shares the same entry band but caps support at TRL 5.

The correct answer is Rs 5,000 crore. This is the outlay with which the scheme aims to strengthen India's pharmaceutical and medical technology research and development ecosystem. Option A is the amount already committed under the first call, when 41 projects were approved for roughly that sum, so it is a real figure from the announcement but not the outlay, and it is the distractor most likely to be picked. Options B and D are round figures that do not appear in the announcement at all. A useful way to hold this together is to remember that a little under a third of the outlay has been committed in the first round, with evaluation of the remaining first-round applications still going on and results expected over the following month.

The correct answer is Promotion of Research and Innovation in Pharma and MedTech. The scheme is run by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, and it is designed to strengthen the country's pharmaceutical and medical technology research ecosystem by helping start-ups, MSMEs and large companies move up the innovation value chain. Options B, C and D are invented expansions built from similar vocabulary, and such near-miss acronyms are the standard way of setting a distractor. Note that the scheme covers both pharmaceuticals and medical devices, which is why MedTech appears in the name, and that its priority areas include novel medical devices alongside new medicines and complex generics. Candidates should also note that the scheme is meant to help start-ups, MSMEs and large companies alike move up the innovation value chain, so the applicant categories are as worth learning as the name itself.